Can 'double blockbuster' strengthen Amgen's backbone?
Sheridan
Cormac
C
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic / Q000639:trends*; D004345:Drug Industry / Q000191:economics* / Q000639:trends*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000191:economics*; D014481:United States
D000911:Antibodies, Monoclonal